Entecavir treatment of chronic hepatitis D

Clinical Infectious Diseases

Volumn 55, Issue 5, 2012, Pages 645-650

  Kabaçam, Gökhan ^a   Önder, F Ouz ^a   Yakut, Mustafa ^a   Seven, Gülseren ^a   Karatayli, Senem C ^a   Karatayli, Ersin ^a   Savaş, Berna ^a   Idilman, Ramazan ^a   Bozdayi, A Mithat ^a   Yurdaydin, Cihan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; DELTA AGENT HEPATITIS; DRUG EFFICACY; FEMALE; HUMAN; MALE; OPEN STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; STATISTICS, NONPARAMETRIC;

EID: 84864960836     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis459     Document Type: Article

References (20)

1. Yurdayd?n C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat 2010; 17:749-56.
2. Yurdayd?n C, Bozkaya H, Gürel S, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002; 37:266-71.
3. Niro GA, Ciancio A, Tillman HL, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005; 22:227-32.
4. Yurdayd?n C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008; 15:314-21.
5. Wedemeyer H, Yurdayd?n C, Dalekos G, et al. Pegyinterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364:322-31.
6. Sheldon J, Ramos B, Toro C, et al. Does treatment of hepatitis B virus infection reduce hepatitis delta virus replication in HIV-HBV-HDVcoinfected patients? Antiviral Ther 2008; 13:97-102.
7. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7:31-40.
8. Rizzetto M. Hepatitis D: thirty years after. J Hepatol 2009; 50: 1043-50.
9. Yurdayd?n C. Entecavir: a step forward in combating hepatitis B disease. Expert Opin Pharmacother 2008; 9:3095-107.
10. Ishak K, Baptista A, Bianchi I, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-9.
11. Bozday? AM, Aslan N, Bozday? G, et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol 2004; 149:2115-29.
12. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139:1218-29.
13. Nguyen T, Thompson AJV, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52:508-13.
14. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha 2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44:675-84.
15. Reijnders JGP, Rickborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon with and entecavir. J Hepatol 2011; 54:449-54.
16. Boyd A, Lacombe K, Miailhes P, et al. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat 2010; 17:65-76.
17. Schaper M, Rodriguez-Frias F, Jardi R, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol 2010; 52:658-64.
18. Yalcin K, Degertekin H, Yurdaydin C, Bozdayi M, Bozkaya H. The role of HBeAg seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D virus infection in a chronic hepatitis D patient during alpha interferon therapy. Eur J Gastroenterol Hepatol 2003; 15:819-23.
19. Heidrich B, Wedemeyer H, Bekta? M, et al. HBeAg-positive delta hepatitis: virological, biochemical and clinical features in a large European multicenter database [abstr]. Hepatology 2008; 48:1184A.
20. Wu JC, Chen TZ, Huang YS, et al. Natural history of hepatitis D virus superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology 1995; 108:796-802.